Default company panoramic image

Elysium Therapeutics, Inc.

Innovate & Develop technologies to enable effective opioid-based pain management while reducing abuse and preserving human life and dignity.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Danville, CA, USA
  • Currency USD
  • Founded May 2013
  • Employees 2

Company Summary

Elysium's goal is to develop game-changing technologies that will (i) enhance the ability of pain patients and their physicians to employ effective opioid-based pain management, (ii) reduce the costly impact of prescription drug abuse on families and our economy, and (iii) save lives. Our technologies are supported by in vitro and in vivo (including human) data, and have the potential for a rapid 505(b)2 development path to market in ~4 years.


  • Default avatar
    A. Gregory Sturmer
    President and Chief Executive Officer

    Greg is a healthcare executive with over 25 years of strategic and operational experience. Before founding Elysium, Greg was CFO of Signature Therapeutics, where he raised over $60M. Previously, Greg was VP, Finance & Investor Relations at Theravance. Greg was responsible for strategic planning & investor relations from start-up through IPO. He was directly involved in negotiating two landmark deals with GSK that support its ~$4B valuation.

  • Default avatar
    Thomas E Jenkins
    EVP and Chief Scientific Officer

    Tom has more than 20 years experience in the pharmaceutical industry. Before founding Elysium, Tom co-founded Theravance, Inc. then later Signature Therapeutics where he was CSO and primary inventor of all of their technologies and product candidates. Tom led a small, highly productive research team that advanced several compounds through hPOC and attracted $80M in financing. Tom is a recognized leader in opioid abuse-resistance technologies.


  • Default avatar
    Wilson, Sonsini, Goodrich & Rosati
    Default avatar
    Scott Morrison (Ernst & Young)